Royce & Associates LP 89bio, Inc. Transaction History
Royce & Associates LP
- $9.35 Billion
- Q3 2025
A detailed history of Royce & Associates LP transactions in 89bio, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 226,058 shares of ETNB stock, worth $3.35 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
226,058
Previous 226,058
-0.0%
Holding current value
$3.35 Million
Previous $2.22 Million
49.53%
% of portfolio
0.04%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding ETNB
# of Institutions
235Shares Held
156MCall Options Held
774KPut Options Held
6.48M-
Ra Capital Management, L.P. Boston, MA19.9MShares$295 Million5.01% of portfolio
-
Pentwater Capital Management LP Naples, FL11.8MShares$174 Million1.08% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.36MShares$139 Million4.33% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.1MShares$135 Million0.22% of portfolio
-
Suvretta Capital Management, LLC New York, NY8.28MShares$123 Million3.65% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $690M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...